Topoisomerase II / DNA

Class

anthracycline antineoplastic antibiotic; DNA-intercalating agent and topoisomerase II inhibitor

Pathway

intercalates between DNA base pairs, inhibiting DNA and RNA synthesis and triggering topoisomerase II-mediated DNA strand breakage; also generates cytotoxic free radicals, together producing the drug's cytocidal activity

Topoisomerase II is an enzyme that all dividing cells rely on to manage the physical topology of DNA. As the double helix is copied or transcribed, it becomes overwound; topoisomerase II relieves this strain by cutting both DNA strands, passing another segment of the helix through the break, and resealing it. Anthracycline antibiotics, a class of DNA-intercalating agents, wedge themselves flatly between adjacent base pairs of the DNA double helix. This intercalation distorts the helix and interferes with the machinery of DNA and RNA synthesis, while also trapping topoisomerase II in the act of cutting DNA, converting a normally transient, repairable strand break into a stabilized, more damaging lesion. The resulting accumulation of DNA breaks, compounded by additional oxidative damage from free radicals generated by the drug, overwhelms the cell's repair capacity and triggers cell death. Because rapidly dividing cells depend heavily on topoisomerase II activity and are especially vulnerable to DNA damage, this mechanism is broadly useful across proliferative malignancies, including many solid tumors and hematologic cancers. It remains one of the oldest and most widely validated cytotoxic strategies in oncology, forming a backbone of combination chemotherapy regimens across diverse tumor types.